Charles River Laboratories International Inc. (NYSE: CRL)’s stock price has plunge by 1.37relation to previous closing price of 195.11. Nevertheless, the company has seen a 3.32% surge in its stock price over the last five trading sessions. businesswire.com reported 2024-10-17 that WILMINGTON, Mass.–(BUSINESS WIRE)—- $CRL #LIFEatCRL–Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection.
Is It Worth Investing in Charles River Laboratories International Inc. (NYSE: CRL) Right Now?
The price-to-earnings ratio for Charles River Laboratories International Inc. (NYSE: CRL) is above average at 23.38x, Company’s 36-month beta value is 1.37.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 8 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRL is 51.04M, and currently, short sellers hold a 3.87% ratio of that floaft. The average trading volume of CRL on October 18, 2024 was 722.02K shares.
CRL’s Market Performance
CRL stock saw a decrease of 3.32% in the past week, with a monthly decline of -4.04% and a quarterly a decrease of -9.38%. The volatility ratio for the week is 2.30%, and the volatility levels for the last 30 days are 2.55% for Charles River Laboratories International Inc. (CRL). The simple moving average for the past 20 days is 1.63% for CRL’s stock, with a -10.92% simple moving average for the past 200 days.
Analysts’ Opinion of CRL
Evercore ISI, on the other hand, stated in their research note that they expect to see CRL reach a price target of $190, previously predicting the price at $225. The rating they have provided for CRL stocks is “In-line” according to the report published on October 07th, 2024.
BofA Securities gave a rating of “Neutral” to CRL, setting the target price at $215 in the report published on October 02nd of the current year.
CRL Trading at 0.21% from the 50-Day Moving Average
After a stumble in the market that brought CRL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.08% of loss for the given period.
Volatility was left at 2.55%, however, over the last 30 days, the volatility rate increased by 2.30%, as shares sank -5.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.09% lower at present.
During the last 5 trading sessions, CRL rose by +3.32%, which changed the moving average for the period of 200-days by -15.57% in comparison to the 20-day moving average, which settled at $194.60. In addition, Charles River Laboratories International Inc. saw -16.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRL starting from LaPlume Joseph W, who sale 1,780 shares at the price of $199.36 back on Aug 08 ’24. After this action, LaPlume Joseph W now owns 22,521 shares of Charles River Laboratories International Inc., valued at $354,861 using the latest closing price.
Joseph LaPlume, the Officer of Charles River Laboratories International Inc., proposed sale 1,780 shares at $196.63 during a trade that took place back on Aug 08 ’24, which means that Joseph LaPlume is holding shares at $350,000 based on the most recent closing price.
Stock Fundamentals for CRL
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.34 for the gross margin
The net margin for Charles River Laboratories International Inc. stands at 0.11. The total capital return value is set at 0.09. Equity return is now at value 12.54, with 5.56 for asset returns.
Based on Charles River Laboratories International Inc. (CRL), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 4.42.
Currently, EBITDA for the company is 1.03 billion with net debt to EBITDA at 2.58. When we switch over and look at the enterprise to sales, we see a ratio of 3.16. The receivables turnover for the company is 5.35for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
In a nutshell, Charles River Laboratories International Inc. (CRL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
